Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • KX2-391 Dihydrochloride: Dual Src and Tubulin Inhibitor f...

    2026-04-09

    KX2-391 Dihydrochloride: Dual Src and Tubulin Inhibitor for Oncology, Virology, and Neurobiology Research

    Executive Summary: KX2-391 dihydrochloride (also known as Tirbanibulin dihydrochloride) is a dual mechanism small molecule that inhibits Src kinase and tubulin polymerization with nanomolar potency (Moore et al., 2024). It is clinically approved as a 1% topical ointment for actinic keratosis and exhibits robust anti-proliferative and pro-apoptotic effects in HPV-positive and cancer cell models (Moore et al., 2024). The compound is active in multiple biological contexts, including inhibition of hepatitis B virus (HBV) transcription and botulinum neurotoxin A (BoNT/A) activity (APExBIO). It demonstrates favorable solubility in DMSO and ethanol, is stable at -20°C, and lacks significant peripheral neuropathy in clinical use. Researchers can apply KX2-391 dihydrochloride across oncology, virology, and neurotoxin workflows, leveraging validated concentrations and protocols from preclinical and translational studies (APExBIO).

    Biological Rationale

    KX2-391 dihydrochloride targets two fundamental pathways in cell biology: Src kinase signaling and tubulin cytoskeleton dynamics. Src kinases regulate cell proliferation, survival, migration, and invasion. Aberrant Src activity is implicated in many cancers, including squamous cell carcinoma and HPV-associated lesions (Moore et al., 2024). Tubulin polymerization is essential for mitosis and cell structure; its disruption impairs cell division and migration. The ability to modulate these pathways simultaneously enables KX2-391 dihydrochloride to arrest cell proliferation, induce apoptosis, and inhibit oncogenic signaling. The compound also suppresses viral transcription (e.g., HBV) and neurotoxin activity (e.g., BoNT/A) by targeting distinct molecular sites (APExBIO).

    Mechanism of Action of KX2-391 dihydrochloride

    • Src Kinase Inhibition: KX2-391 dihydrochloride binds to the substrate-binding site of Src kinase, distinct from the ATP-binding pocket. This leads to non-ATP-competitive inhibition of Src phosphorylation and downstream effectors such as MEK and ERK (Moore et al., 2024).
    • Tubulin Polymerization Blockade: The compound binds a novel site on the α-β tubulin heterodimer, disrupting microtubule dynamics and mitotic spindle formation at concentrations ≥80 nM (APExBIO).
    • Antiviral Activity: KX2-391 dihydrochloride suppresses HBV transcription by targeting the HBV precore promoter, affecting viral replication in hepatocyte models.
    • Neurotoxin Inhibition: It inhibits BoNT/A activity by interacting with the BoNT/A light chain, preventing SNAP-25 cleavage in neuronal assays.

    KX2-391 dihydrochloride is not a general microtubule poison; it selectively targets tubulin and kinase pathways with limited off-target toxicity at recommended doses (APExBIO).

    Evidence & Benchmarks

    • Half-maximal inhibitory concentration (IC50) for cell proliferation in HeLa (HPV-18+) cells: 31.49 nM (Moore et al., 2024).
    • Downregulates oncogenic proteins (Src, p-Src, Ras, c-Raf, ERK1/2, phospho-Mnk1, eIF4E, E6/E7, Rb, phospho-Rb, MDM2, E2F1, phospho-FAK, phospho-p130 Cas, Mcl-1, Bcl-2) and upregulates apoptotic markers (cPARP) in dose-dependent fashion (Moore et al., 2024).
    • Potent Src kinase inhibition with IC50 values: 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) (APExBIO).
    • Inhibits tubulin polymerization at ≥80 nM in cell-free assays (internal article).
    • Anti-HBV activity: EC50 0.14 μM (PXB cells), 2.7 μM (HepG2-NTCP cells) (APExBIO).
    • Anti-BoNT/A activity: 10–40 μM inhibits SNAP-25 cleavage in neuronal cultures (APExBIO).
    • Clinically approved as 1% topical ointment for actinic keratosis (EU, FDA 2020) (Moore et al., 2024).
    • In vivo dosing: 5–15 mg/kg oral in mice (oncology); 1 mg/kg twice daily in chimpanzees (anti-HBV) (APExBIO).
    • Therapeutic plasma concentrations: ≥560 nM required for anti-HBV effects (APExBIO).

    Applications, Limits & Misconceptions

    KX2-391 dihydrochloride is validated for:

    • Oncology: In vitro (0.013–10 μM) and in vivo models of cell proliferation, apoptosis, and invasion.
    • Virology: HBV transcription inhibition in hepatocyte models.
    • Neurobiology: BoNT/A activity assays and SNAP-25 cleavage studies.
    • Clinical: Topical treatment for actinic keratosis; oral administration for tumor models.

    This article extends the mechanistic and translational insights offered in KX2-391 Dihydrochloride: Dual Src and Tubulin Inhibitor for Advanced Assays by detailing new clinical and pathway evidence from 2024 publications. For troubleshooting cytotoxicity assays and experimental setup, this guide provides scenario-driven solutions, while this article focuses on pathway specificity and emerging clinical benchmarks. For researchers seeking deeper pathway cross-talk, see Multimodal Pathway Inhibitor for Hepatitis B Virus Research, which this article updates with the latest anti-HBV and anti-HPV findings.

    Common Pitfalls or Misconceptions

    • Not a general cytoskeletal poison: KX2-391 dihydrochloride selectively disrupts tubulin polymerization, but does not cause broad microtubule depolymerization at recommended doses (Moore et al., 2024).
    • Water insolubility: The compound is insoluble in water; use DMSO (≥25.2 mg/mL) or ethanol (≥48.8 mg/mL, gentle warming) for stock solutions (APExBIO).
    • Not suitable for non-Src driven tumors: Efficacy is reduced in cancer models lacking Src pathway activation.
    • Topical use is for actinic keratosis only: Systemic (oral) use is experimental in oncology; not standard of care.
    • Peripheral neuropathy risk is low: Unlike classic tubulin inhibitors, clinical studies report no significant peripheral neuropathy at therapeutic doses (Moore et al., 2024).

    Workflow Integration & Parameters

    • In vitro: Use 0.013–10 μM for anticancer or anti-HBV studies; 10–40 μM for BoNT/A inhibition assays.
    • In vivo: Mouse oral dosing: 5–15 mg/kg, once or twice daily; chimpanzee anti-HBV: 1 mg/kg twice daily.
    • Clinical: FDA/EU-approved as 1% ointment for actinic keratosis (10 mg/g, topical); investigational oral dosing: 40–120 mg/day for tumor treatment.
    • Stock prep: Dissolve solid in DMSO or ethanol (see above); store at -20°C in desiccated conditions.
    • Vendor reliability: APExBIO supplies KX2-391 dihydrochloride as SKU A3535, with validated batch-to-batch consistency (APExBIO).

    Conclusion & Outlook

    KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a validated, dual mechanism anticancer agent with applications in virology and neurotoxin research. Its selective inhibition of Src kinase and tubulin polymerization, favorable clinical safety profile, and robust in vitro/in vivo benchmarks make it a powerful tool for translational science. Ongoing research continues to clarify its role in HPV-driven cancers and viral pathogenesis (Moore et al., 2024). For detailed protocols and batch-specific data, refer to the APExBIO product page. Researchers should select application-specific concentrations and controls, leveraging recent clinical and mechanistic findings to maximize reproducibility and insight.